What we do Medico Remedies Limited manufactures and markets pharmaceutical formulations focused on anti-infectives, beta-lactams, anti-malarial, and various therapeutic segment drugs. |
Founded in 1,994 |
Market share Strong presence in domestic and international pharmaceutical formulation markets with notable clients and growing revenue. |
Problem solved Addresses healthcare needs by providing essential and specialized medicines including antibiotics, antivirals, and supplements. |
Top clients or who we serve Serves Indian and foreign pharmaceutical companies, government health services; primarily B2B customers. |
Key management Haresh Mehta, Chairman & Whole-Time Director; Harshit Mehta, Managing Director; other experienced board members. |
Our journey and innovations Incorporated 1994, expanded manufacturing facilities in 1999 and 2002, public listing in 2018, ongoing growth and acquisition of adjoining unit. |
Where we operate Operations primarily in India with exports to international pharmaceutical companies. |
Top products or what we offer Anti-infectives, beta-lactams (penicillin and cephalosporins), antimalarials, antiretrovirals, anti-ulcer drugs, vitamins, and other formulations. |
Top brands Multiple pharmaceutical formulations specialized in anti-infective and chronic disease segments; licensed products enhance revenue. |
Raw materials needed Active pharmaceutical ingredients for antibiotics, antivirals, and various therapeutic drugs. |
Raw materials supplier Supplied by various pharmaceutical raw material providers (specific suppliers not disclosed). |
Recurring vs cyclical contribution Revenue is predominantly recurring from ongoing formulation sales and license fees. |
Our industry position Established player in pharmaceutical formulation manufacturing with diversified therapeutic offerings and steady growth. |
Financial highlights FY 2024-25 revenue of Rs. 150.94 crores, net profit Rs. 10.09 crores, showing consistent profitability. |
Geographical revenue split About 7% revenue from India and 45% from outside India as of FY 2017, indicating strong export focus. |
Order book - |
Whats driving growth Expansion of product portfolio, acquisition of manufacturing units, and increasing demand from domestic and export markets. |
Our future plans Capex focused on facility expansion and innovation in pharmaceutical manufacturing capabilities. |
Our green promise - |
Our people and values Committed to ethical practices, safe working environment, and violence-free workplace; emphasis on compliance and governance. |
Key challenges ahead Regulatory compliance, raw material cost fluctuations, competition, and maintaining growth momentum. |
Interesting facts Company listed in 2018 via IPO, expanded facilities by acquiring adjoining manufacturing units enhancing capacity. |
Risks and strategy Mitigates risks via strong internal controls, adherence to regulations, diversified customer base, and robust governance. |
